MK-0616 clinical trials
Also written MK-0616 and Enlicitide Decanoate.
A product of Enlicitide; its studies count on that page too.
How each study uses MK-0616 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MK-0616 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Jul 2026 · LIPFENDRA · NDA 220848 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A brand or code of Enlicitide
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test MK-0616, phase 3 first.
- Nov 2027A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)Phase 3 · Merck Sharp & Dohme LLC
Studies
Open first, then newest update. How each study uses MK-0616 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07058077Written as Enlicitide Decanoate
- A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07821944Written as Enlicitide Decanoate
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)CompletedPhase 1Merck Sharp & Dohme LLCNCT05934292Written as Enlicitide Decanoate
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsCompletedPhase 3Merck Sharp & Dohme LLCNCT05952856Written as Enlicitide Decanoate
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef OutcomesActive, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06008756Written as Enlicitide Decanoate
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)CompletedPhase 3Merck Sharp & Dohme LLCNCT05952869Written as Enlicitide Decanoate
- Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionActive, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06492291Written as Enlicitide Decanoate
- A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)CompletedPhase 1Merck Sharp & Dohme LLCNCT06772792Written as Enlicitide Decanoate
- A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)CompletedPhase 2Merck Sharp & Dohme LLCNCT05261126Written as Enclitide Chloride
- A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)CompletedPhase 1Merck Sharp & Dohme LLCNCT06699329Written as Enlicitide Decanoate
- A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)CompletedPhase 1Merck Sharp & Dohme LLCNCT06699355Written as Enlicitide Decanoate
- A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)CompletedPhase 1Merck Sharp & Dohme LLCNCT06691906Written as Enlicitide decanoate
- The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)CompletedPhase 1Merck Sharp & Dohme LLCNCT06658652Written as Enlicitide decanoate
- A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)CompletedPhase 1Merck Sharp & Dohme LLCNCT06625814Written as Enlicitide Decanoate
- A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT06592339Written as MK-0616
Given beside what is tested · 1 — MK-0616 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call MK-0616 · ClinicalTrials.gg INT002031
- MeSH (NLM) C000728674MK-0616One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000728674 | MK-0616 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.